Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Novartis has initiated a Phase 2a/b study of the VAV1-directed molecular glue degrader MRT-6160 (DDY391) in Sjögren's disease, triggering a $50 million milestone payment to Monte Rosa Therapeutics. The randomized, double-blind, placebo-controlled, multi-center trial will evaluate up to 52 weeks of treatment to support Phase 3 dose selection, and Monte Rosa is eligible for additional Phase 2 study initiation milestones across immune-mediated diseases. Under the global exclusive license, Novartis funds and conducts Phase 2 development; Monte Rosa is eligible for up to $2.1 billion in development, regulatory, and sales milestones, will co-fund Phase 3, shares 30% of U.S.
Key figures
- Drug Name
- MRT-6160 (DDY391)
- Phase Of Trial
- Phase 2a/b
- Nct id
- NCT07737743
- Trial duration weeks
- 52
- Us profit loss share
- 30%
- Milestone payment usd
- 50000000
- Phase1 vav1 degradation
- >90% in peripheral blood T cells
- Potential total milestones usd
- 2100000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.